Cargando…
Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening
The rise of multi- and extensively drug-resistant Mycobacterium tuberculosis (M. tb) strains and co-infection with human immunodeficiency virus has escalated the need for new anti-M. tb drugs. Numerous challenges associated with the M. tb, in particular slow growth and pathogenicity level 3, discour...
Autores principales: | Grzelak, Edyta M., Choules, Mary P., Gao, Wei, Cai, Geping, Wan, Baojie, Wang, Yuehong, McAlpine, James B., Cheng, Jinhua, Jin, Yingyu, Lee, Hanki, Suh, Joo-Won, Pauli, Guido F., Franzblau, Scott G., Jaki, Birgit U., Cho, Sanghyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760628/ https://www.ncbi.nlm.nih.gov/pubmed/31292530 http://dx.doi.org/10.1038/s41429-019-0205-9 |
Ejemplares similares
-
Residual Complexity
Does Impact Organic Chemistry
and Drug Discovery: The Case of Rufomyazine and Rufomycin
por: Choules, Mary P., et al.
Publicado: (2018) -
Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus
por: Choules, Mary P., et al.
Publicado: (2019) -
Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models
por: Ekins, Sean, et al.
Publicado: (2013) -
In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
por: Warit, Saradee, et al.
Publicado: (2017) -
Rufomycin Exhibits Dual Effects Against Mycobacterium abscessus Infection by Inducing Host Defense and Antimicrobial Activities
por: Park, Cho Rong, et al.
Publicado: (2021)